Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Insulin Delivery Jul 08 | 2020Tandem Partners with JDRF for Diabetes Device Education Campaign; Livongo's myStrength App Available for Free to Priority Health MembersPurchase Blast
$599
Posted in: Glucose Monitoring Jul 07 | 2020Nemaura Files PMA for Non-invasive CGM; Medtronic launches Mio Advance Infusion SetPurchase Blast
$599
Posted in: Basal Insulin Jul 06 | 2020New Lilly QW Insulin Ph2 Trials in T1DM and T2DMPurchase Blast
$599
Posted in: Autologous, CAR-T, CD19 Jul 03 | 2020Novartis Ph1b PORTIA Results Presented at Virtual AACR IIPurchase Blast
$599
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Jul 03 | 2020Two New Gracell Early Ph1 Trials in MM and NHL PostedPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jun 30 | 2020Biocorp Partners with Roche in France for Mallya DistributionPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jun 29 | 2020Abbott/Tandem Finalize AID Partnership; What is Tandem’s Role?Purchase Blast
$599
Posted in: Glucose Monitoring Jun 25 | 2020Menarini Launches GlucoMen CGM in EuropePurchase Blast
$599
Posted in: GLP-1RA, Glucagon Jun 24 | 2020Lilly Launches Educational Initiative; Thane Wettig Joins FibroGen; Tandem Acquires Sugarmate; BI Doses First Patient in Ph2 Dual-agonist Trial; IM Therapeutics Doses First Patient with Novel T1DM TherapyPurchase Blast
$599
Posted in: Insulin Delivery Jun 23 | 2020Companion Medical's InPen Approved in Peds; BrightInsight Secures $40M Series B FundingPurchase Blast
$599
Posted in: GLP-1RA, SGLT2i Jun 22 | 2020DAPA-HF CHMP Opinion This Week?; CHMP Agenda June 22-25Purchase Blast
$599
Posted in: Autologous, CAR-T, CD19 Jun 22 | 2020Autolus Ph1/2 ALLCAR19 Results and EHA 2020 Investor Call SummaryPurchase Blast
$599
Posted in: Glucose Monitoring Jun 22 | 2020Libre 2 AID Compatibility Issue Worse Than ExpectedPurchase Blast
$599
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jun 19 | 2020Ziopharm Appoints Carl June as Chairman of Scientific Advisory BoardPurchase Blast
$599
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jun 19 | 2020Thoughts on Ziopharm’s CAR-T And TCR-T Program Updates, Including Their Rapid Personalized Manufacturing Technology; Q1 2020 CallPurchase Blast